BioScrip Inc. said Wednesday that a group of its shareholders now plan to sell more of their shares of the company’s common stock in an underwritten public offering.

The company said the shareholders priced the offering and now plan to sell 6.9 million shares, up from their previously planned 6.8 million shares. The shareholders also granted the offering’s underwriter — Morgan Stanley & Co. — a 30-day option to buy up to an additional 1 million shares.

BioScrip won’t receive any of the proceeds from the sale. The offering is expected to close on or about Monday.

BioScrip, based in Elmsford, N.Y., provides home infusion and pharmacy benefit management services. Its shares fell 76 cents, or 5 percent, to $13.41 in afternoon trading after dropping as low as $13.15 earlier in the day.